Novo to Buy Catalent for $11.5B to Boost Wegovy Supply
Favicon 
www.newsmax.com

Novo to Buy Catalent for $11.5B to Boost Wegovy Supply

Novo Holdings‚ parent of Novo Nordisk‚ will buy contract drugmaker Catalent for $11.5 billion in cash to help meet the strong demand for its popular weight-loss drug Wegovy‚ the companies said Monday.